- In May 2024, a potential male birth control injection, targeting the STK33 protein to render sperm immobile, has shown promise in mice. Injected twice daily for 21 days, male mice were temporarily infertile, with only one out of 13 mice impregnating a female after treatment. Infertility reversed three weeks after cessation of treatment, with no recorded side effects. Researchers aim to test an oral version in primates. While effective, experts suggest other approaches, such as the NES/T gel containing synthetic hormones, may offer faster results in humans
- In May 2024, a recent study conducted by Rutgers Health experts revealed that infertility treatment patients face an increased risk of post-delivery hospitalization for heart disease compared to spontaneously conceived patients. Analyzing over 31 million hospital records, researchers found that infertility patients were twice as likely to be hospitalized for heart disease and hypertension in the year following delivery. The study emphasizes the importance of early postpartum checkups, particularly for patients who undergo infertility treatment to conceive
- In February 2024, Lupin Limited launched Ganirelix Acetate Injection, 250 mcg/0.5 mL, single-dose prefilled syringe in the U.S. Approved by the FDA, it is a generic equivalent to Organon USA LLC's Ganirelix Acetate Injection. The treatment aims to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation
- In June 2023, Quantum Health partnered with Progyny, Inc. to introduce Quantum Health’s Comprehensive Care Solutions platform for family building and fertility solutions
- In April 2023, Cryoport, Inc. signed 3 years supply chain agreement with the Boston IVF to support the reproductive material shipment across the U.S.
